

## **P11. ASPECTS REGARDING THE EVOLUTION OF A GROUP OF PATIENTS WITH MYELODYSPLASTIC SYNDROME IN THE HEMATOLOGY CLINIC OF ARAD**

***Cotoraci Coralina<sup>1,2</sup>, Laza Damian<sup>2</sup>, Onel Mircea<sup>1</sup>, Sasu Alciana<sup>1 2</sup>***

<sup>1</sup> „Vasile Goldiş” Western University of Arad, Romania

<sup>2</sup> Hematology Clinic, Emergency Clinical County Hospital of Arad, Romania

Myelodysplastic syndrome is a relatively new pathological entity, and, because of its preleukemic character it has been carefully studied in the recent years. This paper aims to present the evolution of a group of 16 patients followed in the past year in the Hematology Clinic of Arad. Patients' data were collected retrospectively, paying attention to the diagnostic criteria and the type of disease, to the onset of the disease, treatment protocols and disease evolution. There were a couple of patients with MDS RAEB 1 and 2 which, under tretinoin treatment, had a favorable evolution in time without progression toward acute leukemia. The study also emphasises the transfusion dependance in this group, the onset of secondary hemochromatosis and the iron chelation therapy and its effects on those patients. Being a group of disorders that are usually difficult to diagnose, myelodysplasia is often underdiagnosed; the therapy with tretinoin, initiated at the proper moment after the diagnosis, has, in our clinic experience, a positive impact on the disease, prolonging the survival of these patients.